Literature DB >> 32403109

Respiratory Muscle and Lung Function in Lung Allograft Recipients: Association with Exercise Intolerance.

Jens Spiesshoefer1,2, Carolin Henke3, Hans Joachim Kabitz4, Jerzy Roch Nofer5,6, Michael Mohr7, Georg Evers7, Jan-Kolia Strecker8, Tobias Brix9, Winfried Johannes Randerath10,11, Simon Herkenrath10,11, Lars Henning Schmidt7, Matthias Boentert3.   

Abstract

BACKGROUND: In lung transplant recipients (LTRs), restrictive ventilation disorder may be present due to respiratory muscle dysfunction that may reduce exercise capacity. This might be mediated by pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).
OBJECTIVE: We investigated lung respiratory muscle function as well as circulating pro-inflammatory cytokines and exercise capacity in LTRs.
METHODS: Fifteen LTRs (6 female, age 56 ± 14 years, 63 ± 45 months post-transplantation) and 15 healthy controls matched for age, sex, and body mass index underwent spirometry, measurement of mouth occlusion pressures, diaphragm ultrasound, and recording of twitch transdiaphragmatic (twPdi) and gastric pressures (twPgas) following magnetic stimulation of the phrenic nerves and the lower thoracic nerve roots. Exercise capacity was quantified using the 6-min walking distance (6MWD). Plasma IL-6 and TNF-α were measured using enzyme-linked immunosorbent assays.
RESULTS: Compared with controls, patients had lower values for forced vital capacity (FVC; 81 ± 30 vs.109 ± 18% predicted, p = 0.01), maximum expiratory pressure (100 ± 21 vs.127 ± 17 cm H2O, p = 0.04), diaphragm thickening ratio (2.2 ± 0.4 vs. 3.0 ± 1.1, p = 0.01), and twPdi (10.4 ± 3.5 vs. 17.6 ± 6.7 cm H2O, p = 0.01). In LTRs, elevation of TNF-α was related to lung function (13 ± 3 vs. 11 ± 2 pg/mL in patients with FVC ≤80 vs. >80% predicted; p < 0.05), and lung function (forced expiratory volume after 1 s) was closely associated with diaphragm thickening ratio (r = 0.81; p < 0.01) and 6MWD (r = 0.63; p = 0.02).
CONCLUSION: There is marked restrictive ventilation disorder and respiratory muscle weakness in LTRs, especially inspiratory muscle weakness with diaphragm dysfunction. Lung function impairment relates to elevated levels of circulating TNF-α and diaphragm dysfunction and is associated with exercise intolerance.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Exercise capacity; Lung transplantation; Pro-inflammatory cytokines; Respiratory muscle function

Mesh:

Substances:

Year:  2020        PMID: 32403109     DOI: 10.1159/000507264

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  4 in total

Review 1.  Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential.

Authors:  Jens Spiesshoefer; Binaya Regmi; Matteo Maria Ottaviani; Florian Kahles; Alberto Giannoni; Chiara Borrelli; Claudio Passino; Vaughan Macefield; Michael Dreher
Journal:  Front Physiol       Date:  2022-06-23       Impact factor: 4.755

Review 2.  Diaphragm and Phrenic Nerve Ultrasound in COVID-19 Patients and Beyond: Imaging Technique, Findings, and Clinical Applications.

Authors:  Zaid Patel; Colin K Franz; Ankit Bharat; James M Walter; Lisa F Wolfe; Igor J Koralnik; Swati Deshmukh
Journal:  J Ultrasound Med       Date:  2021-03-27       Impact factor: 2.754

3.  Dyspnea, effort and muscle pain during exercise in lung transplant recipients: an analysis of their association with cardiopulmonary function parameters using machine learning.

Authors:  Fausto Braccioni; Daniele Bottigliengo; Andrea Ermolao; Marco Schiavon; Monica Loy; Maria Rita Marchi; Dario Gregori; Federico Rea; Andrea Vianello
Journal:  Respir Res       Date:  2020-10-15

4.  Ultrasound assessment of the rectus femoris in patients with chronic obstructive pulmonary disease predicts poor exercise tolerance: an exploratory study.

Authors:  Mingming Deng; Chaonan Liang; Yan Yin; Jun Shu; Xiaoming Zhou; Qiuyue Wang; Gang Hou; Chen Wang
Journal:  BMC Pulm Med       Date:  2021-09-25       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.